Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis that primarily affects the lungs. According to the World Health Organisation, around 10.8 million people suffered from tuberculosis in 2023, including 6 million men, 3.6 million women, and 1.3 million children. Tuberculosis is curable and preventable. However, multidrug-resistant tuberculosis poses a significant health challenge, with only 2 in 5 drug-resistant tuberculosis patients able to access treatments in 2023. Thus, the emergence of multidrug-resistant tuberculosis strains is accelerating the development of new drugs that are effective against resistant forms.
Major companies involved in the tuberculosis pipeline drugs market include GlaxoSmithKline and Serum Institute of India Pvt. Ltd., among others.
Leading drugs currently under the pipeline include Sudapyridine (WX-081) and VPM1002, among others.
The rising incidence of drug-resistant tuberculosis and the growing public-private partnerships between research institutions and pharmaceutical companies are anticipated to accelerate the availability of new treatments.
The Tuberculosis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into tuberculosis drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for tuberculosis. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The tuberculosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from tuberculosis.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to tuberculosis.
Tuberculosis (TB) is a multisystemic disease that usually attacks the lungs but can spread to other parts of the body. It is estimated that a quarter of the global population has been infected with the tuberculosis bacteria. Studies show that nearly 5 to 10% of individuals infected with tuberculosis tend to develop symptoms and TB disease. Certain factors such as a weakened immune system, tobacco use, and diabetes, among others, can increase a person’s risk for tuberculosis.
Treatment for tuberculosis includes a combination of antibiotics, with the treatment duration typically lasting for four, six, or nine months. Isoniazid, rifampin, moxifloxacin, pyrazinamide, ethambutol, and rifapentine are some of the popular antibiotics that are prescribed to patients. Advancements in biotechnology and pharmacology such as high-throughput screening and computational modeling are expected to expedite the development of new drugs. Moreover, the rising investment in tuberculosis research and treatment programs are anticipated to fuel the drug pipeline expansion in the coming years.
This section of the report covers the analysis of tuberculosis drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for tuberculosis. Currently, there are around 55 drugs undergoing Phase II clinical development.
The drug molecule categories covered under the tuberculosis pipeline analysis include monoclonal antibody, small molecule, and peptide. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for tuberculosis.
The EMR report for the tuberculosis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in tuberculosis clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Shanghai Jiatan Pharmatech Co., Ltd, the objective of this Phase III, multicenter, double-blind, active-controlled Phase III study is to examine the efficacy and safety of the drug candidate Sudapyridine (WX-081) in combination with a background regimen for the treatment of rifampicin-resistant pulmonary tuberculosis. The study is expected to be completed by October 2026 and has around 450 participants.
Serum Institute of India Pvt. Ltd. is conducting a Phase III clinical trial aimed at investigating the safety and efficacy of VPM1002 compared to BCG SII against tuberculosis infection in infants. The interventional study has enrolled an estimated 6940 subjects and is expected to be completed by December 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Tuberculosis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for tuberculosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within tuberculosis pipeline insights.
Global Tuberculosis Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share